We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Leica Biosystems Launches Advanced Staining Solution for Increased Speed, Quality and Diagnostic Productivity

By LabMedica International staff writers
Posted on 02 Jun 2022
Print article
Image: BOND-PRIME Advanced Staining Solution (Photo courtesy of Leica Biosystems)
Image: BOND-PRIME Advanced Staining Solution (Photo courtesy of Leica Biosystems)

Leica Biosystems (Nussloch, Germany) has launched BOND-PRIME, a premium advanced staining solution, to advance diagnostic productivity in the lab. BOND-PRIME is the only system that delivers all elements of universal access, enabling lab technicians to load any slides in any combination, with any reagent, at any time.

The BOND-PRIME staining platform was developed with the lab's needs in mind: in today's fast-paced health care environment, adaptability is essential to ensure that slides are processed in a timely manner. Universal Access on BOND-PRIME seamlessly adapts and optimizes workflow to stain slides as needed, leaving no slide staining position unutilized. BOND-PRIME features 70 open-access reagent positions and can process up to 72 slides seamlessly, helping to eliminate delays and facilitating continuous workflows.

Single or STAT slides may be turned around in as fast as one hour, enabling pathologists to deliver a diagnosis quickly to patients who need answers quickly. In addition to adaptability and speed, BOND-PRIME consistently delivers the crisp, clean stains that are needed for a definitive diagnosis. The instrument's progressive automation works in tandem with Novocastra premium reagents to produce crisp, high-quality staining in an average of 90 minutes.

"With IHC turnaround time shortened to an average of only 90 minutes, and 100% instrument utilization without constant attention, the BOND-PRIME stainer's impact on workflow is truly impressive," said Colin White, Senior Vice President of Advanced Staining and Imaging.

"We have a history of innovation to address customer needs," said Gustavo Perez-Fernandez, President at Leica Biosystems. "From ensuring STAT cases are processed efficiently, to decreasing the number of cases left pending, BOND-PRIME presents a quantifiable benefit to mid-sized and large laboratories."

Related Links:
Leica Biosystems 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.